The DLAT Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 liver adenocarcinoma cell line. This loss-of-function model targets the DLAT gene, which encodes the dihydrolipoamide S-acetyltransferase (E2) component of the mitochondrial pyruvate dehydrogenase complex (PDC). The polyclonal nature yields a heterogeneous mix of alleles, making it suitable for studies not requiring clonal homogeneity. CRISPR/Cas9-mediated gene disruption abrogates DLAT function in the majority of cells, providing a versatile tool for investigating pyruvate metabolism and cancer cell physiology.
The SK-HEP-1 host cell line was established from the ascitic fluid of a liver adenocarcinoma patient and is widely used as a hepatocellular carcinoma (HCC) model. This epithelial tumor cell line exhibits metabolic profiles typical of cancer cells, including aerobic glycolysis and altered mitochondrial function, rendering it an ideal platform for examining oncogenic signaling and metabolic regulation in liver-derived malignancies.
DLAT encodes the E2 core subunit of the PDC, which catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA, bridging glycolysis and the TCA cycle. The E2 component interacts with E1 (PDHA1/PDHB), E3 (DLD), and PDHX to form the catalytic complex. PDC activity is regulated by pyruvate dehydrogenase kinases (PDK1?C4) and phosphatases (PDP1?C2), with upstream signals including insulin and HIF1A. DLAT knockout disrupts PDC assembly and pyruvate oxidation, reducing acetyl-CoA, citrate, and ATP synthesis while promoting metabolic rewiring toward alternative substrates. This perturbation places DLAT at the nexus of metabolic reprogramming, relevant to the Warburg effect in cancer.
In SK-HEP-1 cells, DLAT deficiency serves as a model to study mitochondrial pyruvate oxidation’s role in tumor survival and metabolic plasticity. Hepatocellular carcinoma frequently exhibits altered PDC activity influencing aggressiveness and therapy response. Loss of DLAT forces a metabolic shift away from oxidative metabolism, potentially revealing vulnerabilities to inhibitors of alternate pathways. The polyclonal population captures phenotypic diversity, mirroring tumor heterogeneity, and is valuable for examining lactic acidosis and the intersection of mitochondrial function with oncogenic signaling.
Applications include Western blotting, RT-qPCR, and PDC activity assays for validation. Seahorse metabolic flux analysis (OCR/ECAR), LC-MS metabolomics, and glucose/lactate measurements characterize metabolic adaptation. Cell proliferation and apoptosis assays under nutrient stress probe functional outcomes. This model supports cancer metabolism research, Warburg effect studies, mitochondrial disorder modeling, and therapeutic target validation in HCC and other cancers. For technical inquiries, contact Ascent Research.
